NCT04004221

Study of Tislelizumab in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer

A Single-Arm, Multicenter Phase 2 Study of BGB-A317 in Patients With Previously Treated PD-L1+ Locally Advanced or Metastatic Urothelial Bladder Cancer

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 113 (actual)
• Sponsor: BeiGene · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This was a single-arm, multicenter, Phase 2 study to evaluate the efficacy and safety of the anti- programmed cell death-1(PD-1) monoclonal antibody BGB-A317 in participants with PD-L1+, locally advanced or metastatic Urothelial Bladder Cancer (UBC) who have progressed during or following a platinum-containing regimen

Conditions

• Locally Advanced or Metastatic Urothelial Bladder Cancer

Interventions

Type	Name	Description
DRUG	Tislelizumab	200mg intravenously (IV) every 3 weeks (Q3W)

Timeline

• Start date: 2017-06-16
• Primary completion: 2019-09-16
• Completion: 2021-03-11
• First posted: 2019-07-01
• Last updated: 2024-10-26
• Results posted: 2023-03-16

Locations

27 sites across 2 countries: China, South Korea